Approximately 2,496 bottles of Anagrelide Capsules (anagrelide USP), a prescription medication used to treat high platelet counts, are being recalled because the drug may not dissolve properly. When a medication fails dissolution specifications, it may not be absorbed by the body at the correct rate, which can lead to the treatment being less effective than intended. These 1 mg capsules were sold in 100-count bottles across the United States and Puerto Rico. Consumers should consult their healthcare provider or pharmacist for a replacement and to ensure their platelet levels remain managed.
The capsules failed dissolution testing, meaning the active medication may not release into the body as required. This can result in reduced drug efficacy, which may fail to properly manage platelet levels in patients who rely on this medication.
Return unused product for a refund.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.